Biostage names chief science officer
Courtesy
Dr. Harout DerSimonian will be Biostage's first chief science officer.
Holliston biotechnology firm Biostage has named Harout DerSimonian to the newly created position of chief science officer as the company closes in on human trials of its Cellspan esophageal implants.
Dr. DerSimonian will direct and manage the cell biology, materials science and other scientific research that forms the basis of Biostage's Cellframe technology platform, the company announced in a release Thursday.
"The complexity of what we are doing, combined with the number of potential applications of our technology, necessitate that Biostage augment the leadership and management of our scientific research. Harout has the necessary cellular and molecular technology expertise, along with an impressive record of achievement in cell therapy programs to support our path to commercialization for our Cellframe technology,” Biostage CEO Jim McGorry said in a statement.
Dr. DerSimonian has over 20 years of experience in developing immunotherapy and cell therapy programs and was instrumental in directing the science that enabled the first FDA-approved clinical trial using autologous human stem cells for cardiac repair, according to Biostage.
Biostage is a biotechnology company developing bioengineered organ implants to treat cancers. The Holliston company, formerly known as Harvard Apparatus Regenerative Technology, announced in May that it has successfully regenerated a segment of esophagus in a study of the implants conducted with the Mayo Clinic using Yucatan pigs. It has filed for a designation with the U.S. Food & Drug Administration that would allow for a full exemption from the agency's registration fees.
WBJ Web Partners
Most Recent
Most Recent
0 Comments